Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Lung Cancer

Free Subscription Articles published in PLoS One Retrieve available abstracts of 298 articles: HTML format

Single Articles

January 2026
1. SHWEIKEH E, Al-Rajab M, Lu J, Xu Q, et al
   A deep learning model to enhance lung cancer detection using 'Dual-Branch' model classification approach.
   PLoS One. 2026;21:e0339404.
   PubMed     Abstract available
   
   
   
2. LI Y, Wu J, Long M, Zeng T, et al
   Prediction of differentiation levels in lung adenocarcinoma using peripheral blood inflammatory cytokines and tumor markers.
   PLoS One. 2026;21:e0339414.
   PubMed     Abstract available
   
   
   
3. ZHOU Y, Wang B, Song C, Xie W, et al
   Identification of ACE and HSPB8 as novel drug targets for LUSC treatment and prognosis based on a prognostic model integrating epigenetic regulation and endoplasmic reticulum stress-related genes.
   PLoS One. 2026;21:e0335395.
   PubMed     Abstract available
   
   
   
4. LI C, Jiang J, Ma Z, Yu Z, et al
   Adaptive and migration-enhanced tree seed algorithm for multi-threshold CT image segmentation and lung cancer recognition.
   PLoS One. 2026;21:e0333304.
   PubMed     Abstract available
   
   
   
5. LI Q, Zhang J, Meng S, Tian F, et al
   Correlation between self-regulatory fatigue and physical activity in lung cancer patients undergoing comprehensive treatment.
   PLoS One. 2026;21:e0341077.
   PubMed     Abstract available
   
   
   
6. PAN Y, Ding X, Duan W, Wang L, et al
   A screening strategy based on machine learning for diagnostic biomarkers in small cell lung cancer.
   PLoS One. 2026;21:e0339195.
   PubMed     Abstract available
   
   
   
7. WANG J, Lin L, Qiu LP, Zheng LL, et al
   Assessing in-hospital mortality risk in ICU lung cancer patients using machine learning: An analysis based on the MIMIC-IV database.
   PLoS One. 2026;21:e0341259.
   PubMed     Abstract available
   
   
   
8. BOROWSKA M, Mojsak M, Bebas E, Pauk J, et al
   Machine learning using entropy-based texture features from MRI to differentiate histological subtypes of non-small cell lung cancer identified as metabolically active on PET/MRI.
   PLoS One. 2026;21:e0338373.
   PubMed     Abstract available
   
   
   
9. WEN H, Luo X, Zhong B, Xiao Y, et al
   MLND-IU: A multi-stage detection model of subcentimeter lung nodule with improved U-Net+.
   PLoS One. 2026;21:e0341750.
   PubMed     Abstract available
   
   
   
10. DE-LA-PUENTE-OVEJERO L, Fernandez-Rodriguez A, Francoz S, Aizpurua G, et al
    RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.
    PLoS One. 2026;21:e0341778.
    PubMed     Abstract available
    
    
    
11. SHAH SNA, Issar K, Parveen R
    A hybrid feature extraction framework combining PCA and mutual information for gene expression based lung cancer classification.
    PLoS One. 2026;21:e0342160.
    PubMed     Abstract available
    
    
    
12. QIN S, Zhou S, Liu Y, Su D, et al
    Intratumoral spatial heterogeneity at non-contrast CT predicts histological grading of invasive pulmonary adenocarcinoma: a multicenter retrospective study.
    PLoS One. 2026;21:e0341163.
    PubMed     Abstract available
    
    
    
13. LIN J, Xie X, Zheng X, Shi H, et al
    Global burden and trends of tracheal, bronchus, and lung cancer attributed to occupational exposure to polycyclic aromatic hydrocarbons in regions with different sociodemographic index, 1990-2021.
    PLoS One. 2026;21:e0342250.
    PubMed     Abstract available
    
    
    
14. KUMAR R, Massey S, Albogami S, Aloliqi AA, et al
    Identifying regulatory driver motifs in non-small cell lung carcinoma via a systematic approach.
    PLoS One. 2026;21:e0340798.
    PubMed     Abstract available
    
    
    
15. SHI Z, Fang Z, Qin Q, Gao Y, et al
    Exploring the toxicological mechanisms of Benzo[a]anthracene (BaA) exposure in lung adenocarcinoma (LUAD) via network toxicology, machine learning, and multi-dimensional bioinformatics analysis.
    PLoS One. 2026;21:e0340116.
    PubMed     Abstract available
    
    
    
16. SHAMSABAD FN, Salehi MH, Shams J, Ghazanfari T, et al
    Comparative inhibitory effects of zeolite, sepiolite, and kaolinite on A549 lung cancer cells.
    PLoS One. 2026;21:e0340270.
    PubMed     Abstract available
    
    
    
17. MIYASAKA Y, Yoshida H, Okano N, Shimada H, et al
    AI-based prediction of recurrence after carbon ion radiotherapy for early stage non-small cell lung cancer.
    PLoS One. 2026;21:e0342481.
    PubMed     Abstract available
    
    
    
18. JEON J, Kang J, Park JH, Lee JH, et al
    Sphingolipid metabolism-related genes B4GALNT1 and CERS4 as prognostic biomarkers in lung adenocarcinoma.
    PLoS One. 2026;21:e0340437.
    PubMed     Abstract available
    
    
    
19. KOU K, Cameron J, Dasgupta P, Chen H, et al
    Generation of machine-learning derived cancer vulnerability indicator to determine the spatial burden of cancer outcomes.
    PLoS One. 2026;21:e0319539.
    PubMed     Abstract available
    
    
    
20. LI J, Xie Z, Chen Y, Jin G, et al
    Trends and associations of pulmonary nodule detection rates in China, 2019-2023: A multicenter cross-sectional study based on Real-World Data.
    PLoS One. 2026;21:e0343207.
    PubMed     Abstract available
    
    
    
21. ESHET Y, Domachevsky L, Tau N, Founshtein GP, et al
    Rapidly progressive arthropathy identified on imaging of patients treated with Crizotinib for ALK-rearranged/ROS1-positive non small cell lung cancer: A retrospective single-center study.
    PLoS One. 2026;21:e0333223.
    PubMed     Abstract available
    
    
    
22. XIANG AP, Yuan XF, Qin ZQ
    Survival study of cytoreductive prostatectomy for prostate cancer with lung metastasis: A propensity score matching study based on the SEER database.
    PLoS One. 2026;21:e0342758.
    PubMed     Abstract available
    
    
    
23. ZHAO W, Yi L, Wu G, Gao Z, et al
    C1RL-AS1/microRNA-424-5p/adrenoceptor beta2 axis: A novel regulatory mechanism in lung adenocarcinoma associated with immune infiltration and prognosis.
    PLoS One. 2026;21:e0343805.
    PubMed     Abstract available
    
    
    
24. JI C, Yao Y, Gui M
    Analysis and prediction of the burden of lung cancer attributable to diet low in fruits in China and the global from 1990 to 2021.
    PLoS One. 2026;21:e0342584.
    PubMed     Abstract available
    
    
    
25. KIM EY, Kim JS, Jin KN, Cho YJ, et al
    Accuracy and reproducibility of tumor size measurement using a deep-learning-based CDSS in resected lung cancer.
    PLoS One. 2026;21:e0344445.
    PubMed     Abstract available
    
    
    
26. MYERS SP, Tsung C, Chen JC, Gokun Y, et al
    Factors correlated with financial hardship among cancer patients during the COVID-19 pandemic.
    PLoS One. 2026;21:e0342984.
    PubMed     Abstract available
    
    
    
27. BAEISSA HM, Bakhsh T, Shakoori AM, Sindi G, et al
    Correction: Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins.
    PLoS One. 2026;21:e0344592.
    PubMed     Abstract available
    
    
    
28. GODFREY CM, Leech AA, McGann KC, Zhu J, et al
    Cost-effectiveness analysis of artificial intelligence-assisted risk stratification of indeterminate pulmonary nodules.
    PLoS One. 2026;21:e0343492.
    PubMed     Abstract available
    
    
    January 2025
29. KANG SJ, Park J, Choi GS, Kim JG, et al
    Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumors of colorectal cancer.
    PLoS One. 2025;20:e0313438.
    PubMed     Abstract available
    
    
    
30. MAMUDU L, Sulley S, Atandoh PH, Reyes JL, et al
    Disparities in time to treatment initiation of invasive lung cancer among Black and White patients in Tennessee.
    PLoS One. 2025;20:e0311186.
    PubMed     Abstract available
    
    
    
31. CHEN X, Kanhar GM, Hu S, Wu C, et al
    Occult metastases and survival of lung cancer by clinical diagnosis and CT screening: A simulation study.
    PLoS One. 2025;20:e0313544.
    PubMed     Abstract available
    
    
    
32. HUANG T, Ma K, Wang Y
    Characterization and evaluation of the cytotoxic, antioxidant, and anti-human lung cancer properties of copper nanoparticles green-synthesized by fennel extract following the PI3K/AKT/Mtor signaling pathway.
    PLoS One. 2025;20:e0309207.
    PubMed     Abstract available
    
    
    
33. SOBOLEVA A, Kaznatcheev A, Cavill R, Schneider K, et al
    Validation of polymorphic Gompertzian model of cancer through in vitro and in vivo data.
    PLoS One. 2025;20:e0310844.
    PubMed     Abstract available
    
    
    
34. SULLIVAN FM, Mair FS, Anderson W, Chew C, et al
    Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening.
    PLoS One. 2025;20:e0306163.
    PubMed     Abstract available
    
    
    
35. GWON HR, Woo A, Yong SH, Park YM, et al
    Cross-sectional study of lung cancer patients as a potential high-risk factor for abdominal aortic aneurysm.
    PLoS One. 2025;20:e0315898.
    PubMed     Abstract available
    
    
    
36. ABDULLAH S, Altwaijry N, Alnakhli M, ALenezi G, et al
    Novel methotrexate long-acting system using ambroxol coating and hydroxypropyl methylcellulose encapsulation for preferential and enhanced lung cancer efficiency.
    PLoS One. 2025;20:e0314941.
    PubMed     Abstract available
    
    
    
37. ANOSOVA O, Head A, Collins B, Alexiou A, et al
    Estimating the burden of underdiagnosis within England: A modelling study of linked primary care data.
    PLoS One. 2025;20:e0313877.
    PubMed     Abstract available
    
    
    
38. AFZAL M, Abusalah MAHA, Shehzadi N, Absar M, et al
    Investigation of biometabolites and novel antimicrobial peptides derived from promising source Cordyceps militaris and effect of non-small cell lung cancer genes computationally.
    PLoS One. 2025;20:e0310103.
    PubMed     Abstract available
    
    
    
39. ZAPATA DONGO RJ, Fontana D, Mologni L, Faya Castillo JE, et al
    Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer.
    PLoS One. 2025;20:e0308747.
    PubMed     Abstract available
    
    
    
40. WANG Q, Luo Y, Zhao Y, Wang S, et al
    Automated recognition and segmentation of lung cancer cytological images based on deep learning.
    PLoS One. 2025;20:e0317996.
    PubMed     Abstract available
    
    
    
41. JAHAN F, Haque S, Hogg J, Price A, et al
    Assessing the influence of the modifiable areal unit problem on Bayesian disease mapping in Queensland, Australia.
    PLoS One. 2025;20:e0313079.
    PubMed     Abstract available
    
    
    
42. PRAKAIKIETIKUL P, Tajarenmuang P, Losuriya P, Ina N, et al
    Non-cancerous CT findings as predictors of survival outcome in advanced non-small cell lung cancer patients treated with first-generation EGFR-TKIs.
    PLoS One. 2025;20:e0313577.
    PubMed     Abstract available
    
    
    
43. ZHU Q, Fei L
    Cross-ViT based benign and malignant classification of pulmonary nodules.
    PLoS One. 2025;20:e0318670.
    PubMed     Abstract available
    
    
    
44. SHAO K, Du F, Qiu L, Zhang Y, et al
    Comparative analysis of VMAT plans on Halcyon and infinity for lung cancer radiotherapy.
    PLoS One. 2025;20:e0318462.
    PubMed     Abstract available
    
    
    
45. BARBEAU LMO, Beelen NA, Savelkouls KG, Keulers TGH, et al
    MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer.
    PLoS One. 2025;20:e0316716.
    PubMed     Abstract available
    
    
    
46. RABBY MS, Islam MM, Kumar S, Maniruzzaman M, et al
    Identification of potential biomarkers for lung cancer using integrated bioinformatics and machine learning approaches.
    PLoS One. 2025;20:e0317296.
    PubMed     Abstract available
    
    
    
47. KHAN MA, Khan ZA, Husain I, Upadhyay S, et al
    Effects of pressure on the survival and viability of cancer cells in vitro: An analytical study.
    PLoS One. 2025;20:e0311685.
    PubMed     Abstract available
    
    
    
48. HIGASHI S, Yamakuchi M, Hashinokuchi H, Takenouchi K, et al
    Adaptation to acidic conditions that mimic the tumor microenvironment, downregulates miR-193b-3p, and induces EMT via TGFbeta2 in A549 cells.
    PLoS One. 2025;20:e0318811.
    PubMed     Abstract available
    
    
    
49. DIAO S, Wan Y, Huang D, Huang S, et al
    Optimizing Bi-LSTM networks for improved lung cancer detection accuracy.
    PLoS One. 2025;20:e0316136.
    PubMed     Abstract available
    
    
    
50. PAN X, Togka K, Ten Berge H, de Jong L, et al
    Lung cancer screening with volume computed tomography is cost-effective in Greece.
    PLoS One. 2025;20:e0316351.
    PubMed     Abstract available
    
    
    
51. GHIROTTO L, Paci E, Bricci C, Marini S, et al
    Self-blaming as a barrier to lung cancer screening and smoking cessation programs in Italy. A qualitative study.
    PLoS One. 2025;20:e0318732.
    PubMed     Abstract available
    
    
    
52. 
    Retraction: Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer.
    PLoS One. 2025;20:e0320171.
    PubMed    
    
    
    
53. TANG S, Bao Q, Ji Q, Wang T, et al
    Improvement of RT-DETR model for ground glass pulmonary nodule detection.
    PLoS One. 2025;20:e0317114.
    PubMed     Abstract available
    
    
    
54. ALLEN J, Healey G, Macdonald I
    Lung cancer associated autoantibody responses are detectable years before clinical presentation.
    PLoS One. 2025;20:e0315220.
    PubMed     Abstract available
    
    
    
55. LV Z, Liu P, Yang Y, Ji J, et al
    Correction: (-)-Epicatechin regulates endoplasmic reticulum stress and promotes ferroptosis in lung cancer cells via the PERK/eIF2alpha/ATF4 signaling pathway.
    PLoS One. 2025;20:e0320174.
    PubMed     Abstract available
    
    
    
56. HOSSAIN MS, Basak N, Mollah MA, Nahiduzzaman M, et al
    Ensemble-based multiclass lung cancer classification using hybrid CNN-SVD feature extraction and selection method.
    PLoS One. 2025;20:e0318219.
    PubMed     Abstract available
    
    
    
57. LI C, Zhong S, Chen J, Mu X, et al
    TsRNA-49-73-Glu-CTC: A promising serum biomarker in non-small cell lung cancer.
    PLoS One. 2025;20:e0320187.
    PubMed     Abstract available
    
    
    
58. ZHANG DT, Shi GX, Jia JY, Tan FW, et al
    Electroacupuncture for acute postoperative pain during coughing after video-assisted thoracoscopic surgery: study protocol for a pilot randomized controlled trial.
    PLoS One. 2025;20:e0316698.
    PubMed     Abstract available
    
    
    
59. ZHENG Z, Zhu H, Fang L
    Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis.
    PLoS One. 2025;20:e0320189.
    PubMed     Abstract available
    
    
    
60. 
    Correction: Capture of circulating metastatic cancer cell clusters from lung cancer patients can reveal unique genomic profiles and potential anti-metastatic molecular targets: A proof-of-concept study.
    PLoS One. 2025;20:e0321150.
    PubMed     Abstract available
    
    
    
61. JAVRUSHYAN H, Ginovyan M, Harutyunyan T, Gevorgyan S, et al
    Elucidating the impact of Hypericum alpestre extract and L-NAME on the PI3K/Akt signaling pathway in A549 lung adenocarcinoma and MDA-MB-231 triple-negative breast cancer cells.
    PLoS One. 2025;20:e0303736.
    PubMed     Abstract available
    
    
    
62. WANG M, Jiang W, Wei T, Li Z, et al
    Dynamic changes and metabolic function of intestinal flora in patients with postoperative pneumonia after lung cancer surgery.
    PLoS One. 2025;20:e0321016.
    PubMed     Abstract available
    
    
    
63. KIM MS, Kim MS
    Deubiquitination of epidermal growth factor receptor by ubiquitin-specific peptidase 54 enhances drug sensitivity to gefitinib in gefitinib-resistant non-small cell lung cancer cells.
    PLoS One. 2025;20:e0320668.
    PubMed     Abstract available
    
    
    
64. HAO L, Zhang J, Di Y, Qi Z, et al
    Predicting a failure of postoperative thromboprophylaxis in non-small cell lung cancer: A stacking machine learning approach.
    PLoS One. 2025;20:e0320674.
    PubMed     Abstract available
    
    
    
65. EL-TANANI M, Satyam SM, Rabbani SA, Obeidat RM, et al
    Decoding oncogenic secrets of regulator of chromosome condensation 1: A breakthrough mechanistic evidence from breast and lung cancer models.
    PLoS One. 2025;20:e0319748.
    PubMed     Abstract available
    
    
    
66. PRAKAIKIETIKUL P, Wannasopha Y, Euathrongchit J, Tantraworasin A, et al
    CT features and histogram analysis of non-contrast images for differentiating malignant and benign mediastinal lymph nodes in Non-Small Cell Lung Cancer (NSCLC).
    PLoS One. 2025;20:e0321921.
    PubMed     Abstract available
    
    
    
67. GAO C, Liu M, Sun Y, Zhao Z, et al
    Association between advanced lung cancer inflammation index and gallstone prevalence among U.S. adults: A population-based study.
    PLoS One. 2025;20:e0321733.
    PubMed     Abstract available
    
    
    
68. KUO P, Elboudwarej E, Zavodovskaya M, Lin KW, et al
    Trop-2 expression in non-small cell lung cancer.
    PLoS One. 2025;20:e0321555.
    PubMed     Abstract available
    
    
    
69. PONGPIACHAN S, Tipmanee D, Khumsup C, Hirunyatrakul P, et al
    Size-segregated analysis of PAHs in Urban air: Source apportionment and health risk assessment in an Urban canal-adjacent environment.
    PLoS One. 2025;20:e0320405.
    PubMed     Abstract available
    
    
    
70. MALIK V, Mittal R, Gupta D, Juneja S, et al
    Optimizing chemotherapeutic targets in non-small cell lung cancer with transfer learning for precision medicine.
    PLoS One. 2025;20:e0319499.
    PubMed     Abstract available
    
    
    
71. YU W, Long L, Hou Q, Yi B, et al
    Development of a nomogram for overall survival prediction in primary upper lobe lung cancer patients: A SEER population-based analysis.
    PLoS One. 2025;20:e0321955.
    PubMed     Abstract available
    
    
    
72. MOUSAVI SF, Masoudi S, Rezaei N, Pourghazi F, et al
    Survival assessment and pre-diagnostic risk factors for lung cancer incidence: Insights from the Golestan Cohort Study.
    PLoS One. 2025;20:e0320931.
    PubMed     Abstract available
    
    
    
73. DE-TORRES JP, Giron-Flamenco JJ, Rodriguez M, de la Fuente-Ano A, et al
    Exploring the impact of surgical treatment for lung cancer in patients with Airway Obstruction from a Lung Cancer Screening Program.
    PLoS One. 2025;20:e0320704.
    PubMed     Abstract available
    
    
    
74. OTERO-CARRASCO B, Nevado PT, Munoz RA, Ferreiro GD, et al
    Finding patterns in lung cancer protein sequences for drug repurposing.
    PLoS One. 2025;20:e0322546.
    PubMed     Abstract available
    
    
    
75. RAO S, Wu H, Zhang G, Dong W, et al
    A comparative analysis of the burden, trends and inequalities of tracheal, bronchus, and lung cancer in India from 2000 to 2021: A systematic analysis for the Global Burden of Disease study 2021.
    PLoS One. 2025;20:e0322646.
    PubMed     Abstract available
    
    
    
76. SALOMONSSON A, Ehinger D, Jonsson M, Botling J, et al
    Gene expression-based identification of prognostic markers in lung adenocarcinoma.
    PLoS One. 2025;20:e0310232.
    PubMed     Abstract available
    
    
    
77. LI Z, Zhu Z, Wang P, Hou C, et al
    Diagnostic, prognostic, and immunological roles of FUT8 in lung adenocarcinoma and lung squamous cell carcinoma.
    PLoS One. 2025;20:e0321756.
    PubMed     Abstract available
    
    
    
78. YIN X, Liang HW, Liu Y, Huang W, et al
    Lobectomy versus sublobar resection on survival in patients with stage T1-2N0M0 small cell lung cancer.
    PLoS One. 2025;20:e0324315.
    PubMed     Abstract available
    
    
    
79. 
    Retraction: Efficient lung cancer detection using computational intelligence and ensemble learning.
    PLoS One. 2025;20:e0324356.
    PubMed    
    
    
    
80. PHILIBERT R, Beach SRH, Mills JA, Dawes K, et al
    Epigenetic assessments of alcohol consumption predict mortality in smokers at risk for lung cancer in the prostate, lung, colorectal and ovarian cancer screening trial.
    PLoS One. 2025;20:e0322783.
    PubMed     Abstract available
    
    
    
81. PEREZ AL, Zamora M, Bahena M, Aramburo-Williams R, et al
    The antiangiogenic peptide VIAN-c4551 inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability.
    PLoS One. 2025;20:e0316983.
    PubMed     Abstract available
    
    
    
82. ZHANG Y, Hu Y, Xi J, Wu B, et al
    Critical timing: Impact of delays to surgery on prognosis in stage I-II non-small cell lung cancer.
    PLoS One. 2025;20:e0319357.
    PubMed     Abstract available
    
    
    
83. JIM JR, Rayed ME, Mridha MF, Nur K, et al
    XLLC-Net: A lightweight and explainable CNN for accurate lung cancer classification using histopathological images.
    PLoS One. 2025;20:e0322488.
    PubMed     Abstract available
    
    
    
84. ZHENG Z, Zhu H, Fang L
    Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.
    PLoS One. 2025;20:e0325171.
    PubMed     Abstract available
    
    
    
85. WANG X, Sharpnack J, Lee TCM
    Improving lung cancer diagnosis and survival prediction with deep learning and CT imaging.
    PLoS One. 2025;20:e0323174.
    PubMed     Abstract available
    
    
    
86. ABUMANSOUR H, Abusara OH, Abu-Sini M, Khalil W, et al
    Thionated levofloxacin derivative: Potential repurposing for cancer treatment and synergism with doxorubicin on doxorubicin-resistant lung cancer cells.
    PLoS One. 2025;20:e0324930.
    PubMed     Abstract available
    
    
    
87. XIE W, Zhang Z, Zhao D, Zhang Y, et al
    Cancer disrupts sex hormone-inflammation relationships: Analysis of ALI in males from NHANES 2007-2018.
    PLoS One. 2025;20:e0325796.
    PubMed     Abstract available
    
    
    
88. 
    Retraction: Blocking TLR2 Activity Attenuates Pulmonary Metastases of Tumor.
    PLoS One. 2025;20:e0326513.
    PubMed    
    
    
    
89. CUI Y, Liu Z
    AKR1C2 silencing promotes ferroptosis and inhibits proliferation, migration, and invasion in lung cancer cells.
    PLoS One. 2025;20:e0325995.
    PubMed     Abstract available
    
    
    
90. WANG X, Liu J, Li C, Duan H, et al
    Latent class analysis of depression among patients with non-small cell lung cancer after surgery: A cross-sectional study.
    PLoS One. 2025;20:e0324723.
    PubMed     Abstract available
    
    
    
91. PUTHDEE N, Mai VH, Settayanon S, Chanvorachote P, et al
    HMGB1-BoxA gene therapy in reversing cisplatin resistance in non-small cell lung cancer.
    PLoS One. 2025;20:e0327144.
    PubMed     Abstract available
    
    
    
92. RENIERS T, Noordzij PG, Veen EJ, Hofman EFN, et al
    Does postoperative plasma IL-6 improve early prediction of infection after pulmonary cancer surgery? A two-centre prospective study.
    PLoS One. 2025;20:e0326537.
    PubMed     Abstract available
    
    
    
93. ZHONG W, Yuan H, Li T, Jin X, et al
    Therapeutic patterns and outcomes in older patients (aged >/= 65 years) with stage III inoperable non-small cell lung cancer (NSCLC): An investigational study from the SEER database.
    PLoS One. 2025;20:e0327458.
    PubMed     Abstract available
    
    
    
94. ABDULKADER-NALLIB I, Cameselle-Teijeiro JM, Lesende-Rodriguez I, Perez-Becerra R, et al
    Next-Generation Sequencing (NGS) in non-small cell lung carcinoma: A real-world experience in the public health system of Galicia (Northwest Spain).
    PLoS One. 2025;20:e0326336.
    PubMed     Abstract available
    
    
    
95. BARBIER MC, Galactionova K, Lambiris M, Oliveira L, et al
    Contributing to a value-based health care framework for lung cancer patients in Switzerland - A methodological approach to merge routinely collected hospital data.
    PLoS One. 2025;20:e0327814.
    PubMed     Abstract available
    
    
    
96. GAO H, Wen X, Sun X, Liu Y, et al
    Contemporaneous symptom networks for multidimensional symptom experience in lung cancer survivors of immunotherapy: A network analysis.
    PLoS One. 2025;20:e0327804.
    PubMed     Abstract available
    
    
    
97. PENG J, Zhang X, Huang Y, Liu C, et al
    Significance of the cribriform pattern in predicting the prognosis of lung adenocarcinoma patients: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0324376.
    PubMed     Abstract available
    
    
    
98. KANG S, Zhao S, Wang X, Pan Z, et al
    Cost-effectiveness of biomarker-directed toripalimab plus chemotherapy for previously untreated extensive-stage small-cell lung-cancer in China.
    PLoS One. 2025;20:e0328730.
    PubMed     Abstract available
    
    
    
99. 
    Correction: Critical timing: Impact of delays to surgery on prognosis in stage I-II non-small cell lung cancer.
    PLoS One. 2025;20:e0328912.
    PubMed     Abstract available
    
    
    
100. CENGIZ MA, Senel T, Kara M
     Bayesian robust symmetric regression for medical data with heavy-tailed errors and censoring.
     PLoS One. 2025;20:e0329589.
     PubMed     Abstract available
     
     
     
101. ZHANG X, Liu J, Zhao Z, Jiang J, et al
     Effects of long-term metformin intake on postoperative clinicopathological characteristics in patients with invasive lung adenocarcinoma and type 2 diabetes mellitus: A retrospective analysis.
     PLoS One. 2025;20:e0329277.
     PubMed     Abstract available
     
     
     
102. SENNA KM, Zimmermann IR, Costa MGSD, Tura BR, et al
     Cost-effectiveness assessment of liquid biopsy for early detection of lung cancer in Brazil.
     PLoS One. 2025;20:e0328631.
     PubMed     Abstract available
     
     
     
103. HARDI H, Fitrianti Z, Utama KE, Vidya AP, et al
     Tailoring oral targeted therapies dosage in lung cancer: A systematic review of pharmacokinetics studies on renal and hepatic impairment.
     PLoS One. 2025;20:e0324056.
     PubMed     Abstract available
     
     
     
104. KHAN AH, Li J, Asghar MN, Iqbal S, et al
     LGD_Net: Capsule network with extreme learning machine for classification of lung diseases using CT scans.
     PLoS One. 2025;20:e0327419.
     PubMed     Abstract available
     
     
     
105. OCHI T, Sakairi Y, Sata Y, Toyoda T, et al
     Indocyanine green intravenous administration can more accurately identify the intersegmental plane than the inflation-deflation method in lung segmentectomy.
     PLoS One. 2025;20:e0328362.
     PubMed     Abstract available
     
     
     
106. ABDOLLAHI A, Favata M, Weber M, Roman V, et al
     The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer.
     PLoS One. 2025;20:e0327588.
     PubMed     Abstract available
     
     
     
107. SUN J, Yang L, Liu D, Xue H, et al
     Diagnostic accuracy of circulating tumor DNA for detection of ALK rearrangement in lung cancer: A systematic review and meta-analysis of 14 studies.
     PLoS One. 2025;20:e0330855.
     PubMed     Abstract available
     
     
     
108. CHEN L, Zhou M, Lv D, Qiu S, et al
     The association between cadmium exposure and lung cancer risk: A protocol for systematic review and meta-analysis.
     PLoS One. 2025;20:e0329660.
     PubMed     Abstract available
     
     
     
109. 
     Correction: Critical timing: Impact of delays to surgery on prognosis in stage I-II non-small cell lung cancer.
     PLoS One. 2025;20:e0330646.
     PubMed     Abstract available
     
     
     
110. 
     Retraction: Wasp venom peptide improves the proapoptotic activity of alendronate sodium in A549 lung cancer cells.
     PLoS One. 2025;20:e0330467.
     PubMed    
     
     
     
111. ZENG Q, Hu T, Chen Z, Zheng J, et al
     YOLO-ED: An efficient lung cancer detection model based on improved YOLOv8.
     PLoS One. 2025;20:e0330732.
     PubMed     Abstract available
     
     
     
112. ARIK A, Cairns AJG, Streftaris G
     Cancer disparities: Projection, COVID-19, and scenario-based diagnosis delay impact.
     PLoS One. 2025;20:e0330752.
     PubMed     Abstract available
     
     
     
113. WANG L, Zhao H, Yang K, Wang Z, et al
     Assessing the real-world safety of docetaxel for non-small cell lung cancer: Insights from a comprehensive analysis of FAERS data.
     PLoS One. 2025;20:e0331979.
     PubMed     Abstract available
     
     
     
114. DAI L, Hu J, Yang Y, Qian B, et al
     1p-Enh-regulated CYP4B1 alleviates NNK-induced heart failure and lung cancer via the STAT3 pathway.
     PLoS One. 2025;20:e0331471.
     PubMed     Abstract available
     
     
     
115. JUNG DM, Kwon YJ, Cho YW, Baek JG, et al
     A volumetric modulated arc therapy-based dynamic conformal arc technique with limited monitor units (VMATliMU) to reduce multileaf collimator interplay effects: A computational phantom study for stage I non-small-cell lung cancer.
     PLoS One. 2025;20:e0332190.
     PubMed     Abstract available
     
     
     
116. NAM AY, Joo SH, Lee NY, Yoon G, et al
     3-O-acetylrubiarbonol B preferentially targets EGFR and MET over rubiarbonol B to inhibit NSCLC cell growth.
     PLoS One. 2025;20:e0329706.
     PubMed     Abstract available
     
     
     
117. ZHAO W, Zhao Z, Wang Y, Yang H, et al
     Artificial intelligence-based CT histogram parameters differentiating bronchiolar adenoma and lung adenocarcinomas: A two-center study.
     PLoS One. 2025;20:e0331336.
     PubMed     Abstract available
     
     
     
118. ZHANG Q, Fu C, Liu S, Leng Y, et al
     Construction and validation of a prognostic model based on mitochondria-associated endoplasmic reticulum membranes gene signature in LUAD patients.
     PLoS One. 2025;20:e0330722.
     PubMed     Abstract available
     
     
     
119. WANG Y, Mustaza SM, Ab-Rahman MS, Mokri SS, et al
     HEE-SegGAN: A holistically-nested edge enhanced GAN for pulmonary nodule segmentation.
     PLoS One. 2025;20:e0328629.
     PubMed     Abstract available
     
     
     
120. XIAO Z, Long Q, Liao J, Huang F, et al
     The role of SLC2A1 in lung adenocarcinoma: From tumorigenesis to patient survival.
     PLoS One. 2025;20:e0324043.
     PubMed     Abstract available
     
     
     
121. KIZILTAN HS, Cepni K
     Prognostic value of D-dimer in treatment and follow up for patients who underwent radiotherapy in advanced lung cancer.
     PLoS One. 2025;20:e0333085.
     PubMed     Abstract available
     
     
     
122. LANG W, Wang J, Ouyang M, Zhao H, et al
     Cost-effectiveness analysis of benmelstobart and anlotinib plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: Perspectives from the United States and China.
     PLoS One. 2025;20:e0331338.
     PubMed     Abstract available
     
     
     
123. QIU X, Hu S, Dong S, Sun H, et al
     Construction of an automated machine learning-based predictive model for postoperative pulmonary complications risk in non-small cell lung cancer patients undergoing thoracoscopic surgery.
     PLoS One. 2025;20:e0333413.
     PubMed     Abstract available
     
     
     
124. ABOALHAIJA N, Abulawi H, Hamed R, Alwahsh M, et al
     Phytochemical characterization, anticancer potential, and nanoemulsion-based delivery of Chiliadenus montanus.
     PLoS One. 2025;20:e0333482.
     PubMed     Abstract available
     
     
     
125. XIAO Y, Lin X, Gong H, Hu J, et al
     The association of POSTN with postoperative recurrence risk in early-stage lung adenocarcinoma: From gene networks to cellular functions.
     PLoS One. 2025;20:e0331590.
     PubMed     Abstract available
     
     
     
126. ZHANG X, Lin J, Fan Z, Zhang S, et al
     The role of lncRNA SNHG15 in UV-induced DNA damage repair.
     PLoS One. 2025;20:e0334414.
     PubMed     Abstract available
     
     
     
127. BAEISSA HM, Bakhsh T, Shakoori AM, Sindi G, et al
     Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins.
     PLoS One. 2025;20:e0334013.
     PubMed     Abstract available
     
     
     
128. NOMORI H, Yue C, Iguchi H, Kashihara K, et al
     Long-term outcomes of combination therapy with stereotactic body radiation therapy plus cryoablation using liquid nitrogen for stage I non-small cell lung cancer with tumors >/=2 cm.
     PLoS One. 2025;20:e0332893.
     PubMed     Abstract available
     
     
     
129. SAITO T, Ishida M, Akama TO, Hattori S, et al
     Clinical and pathological implications of the presence of MECA-79-expressing tumor cells in pathological stage IA lung adenocarcinoma.
     PLoS One. 2025;20:e0323233.
     PubMed     Abstract available
     
     
     
130. ESTIFANOS N, Egata G, Addissie A, Argaw Kebede R, et al
     Lung cancer symptoms awareness among Ethiopian adults: A latent class analysis.
     PLoS One. 2025;20:e0332952.
     PubMed     Abstract available
     
     
     
131. 
     Retraction: Ginkgo biloba Extract Decreases Non-Small Cell Lung Cancer Cell Migration by Downregulating Metastasis-Associated Factor Heat-Shock Protein 27.
     PLoS One. 2025;20:e0335087.
     PubMed    
     
     
     
132. SHAO K, Chai C, Yang Y, Chen W, et al
     Dosimetric comparison of Monte Carlo, Acuros XB, and anisotropic analytical algorithm for lung cancer plans on halcyon accelerators.
     PLoS One. 2025;20:e0334329.
     PubMed     Abstract available
     
     
     
133. NAGASE W, Harada K, Kudo Y, Matsubayashi J, et al
     AI-driven 3D CT imaging prediction model for improving preoperative detection of visceral pleural invasion in early-stage lung cancer.
     PLoS One. 2025;20:e0332956.
     PubMed     Abstract available
     
     
     
134. HUSSAIN T, Son EH, Wallen GR, Yang L, et al
     Symptom profiles in lung cancer survivors: A latent class approach.
     PLoS One. 2025;20:e0309272.
     PubMed     Abstract available
     
     
     
135. MOHAMED Z, Fofana S, Cobos E, Tripathi MK, et al
     Causal predictive modeling of survival of lung and bronchus cancer patients diagnosed during 2010-2011 in Texas.
     PLoS One. 2025;20:e0333477.
     PubMed     Abstract available
     
     
     
136. HOSSEINI E, Tavakoli-Yaraki M, Meamar AR, Ajam Z, et al
     Impact of hydatid cyst laminated layer antigens on cell death rate, apoptosis induction, and key genes in the cell proliferation pathway: Insights from A549 cell line studies.
     PLoS One. 2025;20:e0335188.
     PubMed     Abstract available
     
     
     
137. XUE Y, Wang Y, Huang T, Dong Y, et al
     Construction and validation of an anoikis-related prognostic model for lung adenocarcinoma based on bulk and single-cell transcriptomic data.
     PLoS One. 2025;20:e0335788.
     PubMed     Abstract available
     
     
     
138. YU L, Yu X, Ma C, Zhang X, et al
     Safety and efficacy of radiotherapy combined with immunotherapy in limited-stage small cell lung cancer a single-arm meta-analysis and systematic review.
     PLoS One. 2025;20:e0337459.
     PubMed     Abstract available
     
     
     
139. CHENG M, Zhang J, Jin L, Yu C, et al
     Adjuvant Icotinib in EGFR-mutated stage IB non-small cell lung cancer with high-risk factors: A retrospective case series.
     PLoS One. 2025;20:e0337237.
     PubMed     Abstract available
     
     
     
140. PAEZ R, Ratwani AP, Duke JD, Bridwell G, et al
     Robotic versus electromagnetic bronchoscopy for pulmonary leslon assessment using integrated intraprocedural imaging: Study protocol for the reliant 2 trial.
     PLoS One. 2025;20:e0327611.
     PubMed     Abstract available
     
     
     
141. HAN MTT, Oo TZM, Chewaskulyong B, Pornprasert S, et al
     MiR-125b-5p and miR-100-5p as Biomarkers and therapeutic targets for the prevention of particulate matter-induced non-smoker lung cancer.
     PLoS One. 2025;20:e0337805.
     PubMed     Abstract available
     
     
     
142. DHOUIB W, Maatouk A, Bennasrallah C, Kacem M, et al
     Incidence and survival of Lung Cancer: A retrospective population-based cohort (Monastir, Tunisia: 2002-2022).
     PLoS One. 2025;20:e0338140.
     PubMed     Abstract available
     
     
     
143. HOBSON LM, Martin RM, Smith-Byrne K, Davey Smith G, et al
     A protocol for using human genetic data to identify circulating protein level changes that are the causal consequence of cancer processes.
     PLoS One. 2025;20:e0312970.
     PubMed     Abstract available
     
     
     
144. BAE BK, Kim SJ, Kim JC
     Influence of inter-fractional respiratory motion changes on dose delivery accuracy in dynamic conformal arc lung stereotactic body radiotherapy: A phantom study.
     PLoS One. 2025;20:e0336475.
     PubMed     Abstract available
     
     
     
145. LI J, Shen Z, Liu D, Ma J, et al
     A novel prognostic model for lung squamous cell carcinoma based on multi-omics analysis and machine learning.
     PLoS One. 2025;20:e0336792.
     PubMed     Abstract available
     
     
     
146. WEI S, Zhang L, Liu C, Qi X, et al
     Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System.
     PLoS One. 2025;20:e0339005.
     PubMed     Abstract available
     
     
     
147. YANG Y, Zhao B, Jiang Y, Han X, et al
     Overexpression of PTPRCAP inhibits biological function of lung adenocarcinoma through apoptosis pathway.
     PLoS One. 2025;20:e0337223.
     PubMed     Abstract available
     
     
     
148. EL-TANANI M, Satyam SM, Rabbani SA, El-Tanani Y, et al
     Disruption of epidermal growth factor receptor signaling and cytoskeletal dynamics by mebendazole and gefitinib synergistically impairs paracrine cytokine signaling in non-small cell lung cancer and triple-negative breast cancer Cell lines.
     PLoS One. 2025;20:e0338027.
     PubMed     Abstract available
     
     
     
149. ZHANG Z, Lin Z, Li W, Chen B, et al
     Sestrin3 confers resistance to recombinant human arginase in small cell lung cancer by activating Akt/mTOR/ASS1 axis.
     PLoS One. 2025;20:e0338802.
     PubMed     Abstract available
     
     
     
150. TANG L, Chen Y, Zhan S, Zhu L, et al
     Socazolimab combined with carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis in China.
     PLoS One. 2025;20:e0339663.
     PubMed     Abstract available
     
     
     January 2024
151. ZHANG J, Huang X, Liu Y, Han Y, et al
     GAN-based medical image small region forgery detection via a two-stage cascade framework.
     PLoS One. 2024;19:e0290303.
     PubMed     Abstract available
     
     
     
152. GAO X, Tang M, Tian S, Li J, et al
     ncRNAs-mediated TIMELESS overexpression in lung adenocarcinoma correlates with reduced tumor immune cell infiltration and poor prognosis.
     PLoS One. 2024;19:e0296829.
     PubMed     Abstract available
     
     
     
153. 
     Expression of Concern: Over-Expression of LSD1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung Cancer.
     PLoS One. 2024;19:e0298436.
     PubMed    
     
     
     
154. KANG J, Zhang J, Tian Z, Xu Y, et al
     The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: An updated systematic review and meta-analysis.
     PLoS One. 2024;19:e0276318.
     PubMed     Abstract available
     
     
     
155. FAYA CASTILLO JE, Zapata Dongo RJ, Wong Chero PA, Infante Varillas SF, et al
     Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer.
     PLoS One. 2024;19:e0295966.
     PubMed     Abstract available
     
     
     
156. 
     Expression of Concern: Comparison of 18F-FDG PET/CT and DWI for detection of mediastinal nodal metastasis in non-small cell lung cancer: A meta-analysis.
     PLoS One. 2024;19:e0299045.
     PubMed    
     
     
     
157. TIAN P, Du D, Yang L, Zhou N, et al
     SP3-induced Timeless transcription contributes to cell growth of lung adenocarcinoma cells.
     PLoS One. 2024;19:e0298295.
     PubMed     Abstract available
     
     
     
158. CHEN Q, Li W, Cai N, Chen W, et al
     Comparison of postoperative complications in mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: Protocol for a systematic review and meta-analysis.
     PLoS One. 2024;19:e0298368.
     PubMed     Abstract available
     
     
     
159. MORI S, Ueki Y, Hasegawa M, Nakamura K, et al
     Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study.
     PLoS One. 2024;19:e0298573.
     PubMed     Abstract available
     
     
     
160. WANG H, Tang H, Yuan S, Liang C, et al
     IL-17A deficiency inhibits lung cancer-induced osteoclastogenesis by promoting apoptosis of osteoclast precursor cells.
     PLoS One. 2024;19:e0299028.
     PubMed     Abstract available
     
     
     
161. YOO SJ, Park YS, Choi H, Kim DS, et al
     Prospective evaluation of deep learning image reconstruction for Lung-RADS and automatic nodule volumetry on ultralow-dose chest CT.
     PLoS One. 2024;19:e0297390.
     PubMed     Abstract available
     
     
     
162. AJENU EO, Seideneck AM, Pandellapalli E, Shinsky EM, et al
     ABCG2 transporter reduces protein aggregation in cigarette smoke condensate-exposed A549 lung cancer cells.
     PLoS One. 2024;19:e0297661.
     PubMed     Abstract available
     
     
     
163. KESSLER LG, Comstock B, Aiello Bowles EJ, Mou J, et al
     Protocol to measure validity and reliability of colorectal, breast, cervical and lung cancer screening questions from the 2021 National Health Interview Survey: Methodology and design.
     PLoS One. 2024;19:e0297773.
     PubMed     Abstract available
     
     
     
164. AHMAD A, Kulachi MO, Farman M, Junjua MU, et al
     Mathematical modeling and control of lung cancer with IL2 cytokine and anti-PD-L1 inhibitor effects for low immune individuals.
     PLoS One. 2024;19:e0299560.
     PubMed     Abstract available
     
     
     
165. LEE YJ, Kang N, Nam J, Lee EG, et al
     The preventative effects of statin on lung cancer development in patients with idiopathic pulmonary fibrosis using the National Health Insurance Service Database in Korea.
     PLoS One. 2024;19:e0299484.
     PubMed     Abstract available
     
     
     
166. MALIK H, Anees T
     Multi-modal deep learning methods for classification of chest diseases using different medical imaging and cough sounds.
     PLoS One. 2024;19:e0296352.
     PubMed     Abstract available
     
     
     
167. XUE Y, Zhang D, Jia L, Yang W, et al
     Integrating image and gene-data with a semi-supervised attention model for prediction of KRAS gene mutation status in non-small cell lung cancer.
     PLoS One. 2024;19:e0297331.
     PubMed     Abstract available
     
     
     
168. MAJUMDER S, Gautam N, Basu A, Sau A, et al
     MENet: A Mitscherlich function based ensemble of CNN models to classify lung cancer using CT scans.
     PLoS One. 2024;19:e0298527.
     PubMed     Abstract available
     
     
     
169. ZHANG L, Xu L, Chen Z, You H, et al
     Risk factors and related miRNA phenotypes of chronic pain after thoracoscopic surgery in lung adenocarcinoma patients.
     PLoS One. 2024;19:e0297742.
     PubMed     Abstract available
     
     
     
170. LI Q, Wei Z, Zhang Y, Zheng C, et al
     Causal role of metabolites in non-small cell lung cancer: Mendelian randomization (MR) study.
     PLoS One. 2024;19:e0300904.
     PubMed     Abstract available
     
     
     
171. MOMOKI Y, Ichinose A, Nakamura K, Iwano S, et al
     Development of automatic generation system for lung nodule finding descriptions.
     PLoS One. 2024;19:e0300325.
     PubMed     Abstract available
     
     
     
172. HAN H, Huang H, Chen AP, Tang Y, et al
     High CASC expression predicts poor prognosis of lung cancer: A systematic review with meta-analysis.
     PLoS One. 2024;19:e0292726.
     PubMed     Abstract available
     
     
     
173. ZHANG Y, Liu H, Chang C, Yin Y, et al
     Machine learning for differentiating lung squamous cell cancer from adenocarcinoma using Clinical-Metabolic characteristics and 18F-FDG PET/CT radiomics.
     PLoS One. 2024;19:e0300170.
     PubMed     Abstract available
     
     
     
174. LV M, Li X, Yin Z, Yang H, et al
     Comprehensive analysis and validation reveal DEPDC1 as a potential diagnostic biomarker associated with tumor immunity in non-small-cell lung cancer.
     PLoS One. 2024;19:e0294227.
     PubMed     Abstract available
     
     
     
175. LE ROUX O, Everitt JI, Counter CM
     p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis.
     PLoS One. 2024;19:e0292189.
     PubMed     Abstract available
     
     
     
176. TRIPLETTE M, Kross EK, Snidarich M, Shahrir S, et al
     An alternating-intervention pilot trial on the impact of an informational handout on patient-reported outcomes and follow-up after lung cancer screening.
     PLoS One. 2024;19:e0300352.
     PubMed     Abstract available
     
     
     
177. MAY T, Clement MS, Halait H, Kohlmann A, et al
     Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes.
     PLoS One. 2024;19:e0295987.
     PubMed     Abstract available
     
     
     
178. ZHANG H, Cheng X, Guo W, Zheng C, et al
     Metastasis patterns and prognosis in young gastric cancer patients: A propensity score?matched SEER database analysis.
     PLoS One. 2024;19:e0301834.
     PubMed     Abstract available
     
     
     
179. RADWAN AA, Alanazi F, Al-Dhfyan A
     Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.
     PLoS One. 2024;19:e0298326.
     PubMed     Abstract available
     
     
     
180. LI H, Huntington S, Gross C, Wang SY, et al
     Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease.
     PLoS One. 2024;19:e0300789.
     PubMed     Abstract available
     
     
     
181. ZHANG MS, Yeh YC, Huang HN, Lin LW, et al
     The association of EGFR amplification with aberrant exon 20 insertion report using the cobas EGFR Mutation Test v2.
     PLoS One. 2024;19:e0301120.
     PubMed     Abstract available
     
     
     
182. KONG Y, Hong L, Xu XC, Chen YF, et al
     The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.
     PLoS One. 2024;19:e0301931.
     PubMed     Abstract available
     
     
     
183. WU B, Zhang X, Feng N, Hu Z, et al
     Treatment strategies for stage IA non-small cell lung cancer: A SEER-based population study.
     PLoS One. 2024;19:e0298470.
     PubMed     Abstract available
     
     
     
184. HUH Y, Sohn YJ, Kim HR, Chun H, et al
     Sex differences in prognosis factors in patients with lung cancer: A nationwide retrospective cohort study in Korea.
     PLoS One. 2024;19:e0300389.
     PubMed     Abstract available
     
     
     
185. BAK SH, Park J, Lee S, Kim JH, et al
     Clinical usability of 3D gradient-echo-based ultrashort echo time imaging: Is it enough to facilitate diagnostic decision in real-world practice?
     PLoS One. 2024;19:e0296696.
     PubMed     Abstract available
     
     
     
186. HAN KT, Kim S
     Does improved nurse staffing impact patient outcomes in cancer? Association between chronic diseases and mortality among older adult patients with lung cancer in Korea.
     PLoS One. 2024;19:e0301010.
     PubMed     Abstract available
     
     
     
187. THU YM, Suzawa K, Tomida S, Ochi K, et al
     PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer.
     PLoS One. 2024;19:e0300644.
     PubMed     Abstract available
     
     
     
188. CHANG GC, Shih JY, Yu CJ, Chao HS, et al
     Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.
     PLoS One. 2024;19:e0303046.
     PubMed     Abstract available
     
     
     
189. LEE ACH, Madariaga MLL, Lee SM, Ferguson MK, et al
     The risk analysis index is an independent predictor of outcomes after lung cancer resection.
     PLoS One. 2024;19:e0303281.
     PubMed     Abstract available
     
     
     
190. WANG H, Zhu H, Ding L, Yang K, et al
     Attention pyramid pooling network for artificial diagnosis on pulmonary nodules.
     PLoS One. 2024;19:e0302641.
     PubMed     Abstract available
     
     
     
191. N KACHOUIE N, Deebani W, Shutaywi M, Christiani DC, et al
     Lung cancer clustering by identification of similarities and discrepancies of DNA copy numbers using maximal information coefficient.
     PLoS One. 2024;19:e0301131.
     PubMed     Abstract available
     
     
     
192. 
     Editorial Note: Honokiol Inhibits Non-Small Cell Lung Cancer Cell Migration by Targeting PGE2-Mediated Activation of beta-Catenin Signaling.
     PLoS One. 2024;19:e0303600.
     PubMed    
     
     
     
193. BIANCHI F, Le Noci V, Bernardo G, Gagliano N, et al
     Cigarette smoke sustains immunosuppressive microenvironment inducing M2 macrophage polarization and viability in lung cancer settings.
     PLoS One. 2024;19:e0303875.
     PubMed     Abstract available
     
     
     
194. LUO W, Chang G, Lin D, Xie H, et al
     3,3'-((3,4,5-trifluoropHenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) inhibit lung cancer cell proliferation and migration.
     PLoS One. 2024;19:e0303186.
     PubMed     Abstract available
     
     
     
195. ZHONG J, Hua Y, Zou S, Wang B, et al
     Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway.
     PLoS One. 2024;19:e0299921.
     PubMed     Abstract available
     
     
     
196. BOUKANSA S, Mouhrach I, El Agy F, El Bardai S, et al
     Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report.
     PLoS One. 2024;19:e0298721.
     PubMed     Abstract available
     
     
     
197. PATHAN RK, Shorna IJ, Hossain MS, Khandaker MU, et al
     The efficacy of machine learning models in lung cancer risk prediction with explainability.
     PLoS One. 2024;19:e0305035.
     PubMed     Abstract available
     
     
     
198. CUI R, Li Y, Yu X, Wei C, et al
     Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm meta-analysis.
     PLoS One. 2024;19:e0304941.
     PubMed     Abstract available
     
     
     
199. ALSHEHRI MA, Asiri SA, Helmi N, Baeissa HM, et al
     Unrevealing the multitargeted potency of 3-1-BCMIYPPA against lung cancer structural maintenance and suppression proteins through pharmacokinetics, QM-DFT, and multiscale MD simulation studies.
     PLoS One. 2024;19:e0303784.
     PubMed     Abstract available
     
     
     
200. YU H, Wang Y, Yue X, Zhang H, et al
     Influence of the atmospheric environment on spatial variation of lung cancer incidence in China.
     PLoS One. 2024;19:e0305345.
     PubMed     Abstract available
     
     
     
201. JARRY U, Bostoen M, Archambeau J, Pineau R, et al
     Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer.
     PLoS One. 2024;19:e0304914.
     PubMed     Abstract available
     
     
     
202. WANG C, Zhu X, Zheng M, Chen Y, et al
     Pan-cancer analysis of PSCA that is associated with immune infiltration and affects patient prognosis.
     PLoS One. 2024;19:e0298469.
     PubMed     Abstract available
     
     
     
203. WANG B, Wang J, Sun T, Ding Y, et al
     Lu's approach for video-assisted thoracoscopic surgery.
     PLoS One. 2024;19:e0300632.
     PubMed     Abstract available
     
     
     
204. GONG S, Li G, Li D, Liu Y, et al
     The risk for subsequent primary lung cancer after cervical carcinoma: A quantitative analysis based on 864,627 cases.
     PLoS One. 2024;19:e0305670.
     PubMed     Abstract available
     
     
     
205. 
     Correction: Efficient gene transfection to lung cancer cells via Folate-PEI-Sorbitol gene transporter.
     PLoS One. 2024;19:e0306665.
     PubMed     Abstract available
     
     
     
206. USHER-SMITH JA, Masson G, Godoy A, Burge SW, et al
     Acceptability of adding a non-contrast abdominal CT scan to screen for kidney cancer and other abdominal pathology within a community-based CT screening programme for lung cancer: A qualitative study.
     PLoS One. 2024;19:e0300313.
     PubMed     Abstract available
     
     
     
207. PARK J, Rho MJ, Moon MH
     Enhanced deep learning model for precise nodule localization and recurrence risk prediction following curative-intent surgery for lung cancer.
     PLoS One. 2024;19:e0300442.
     PubMed     Abstract available
     
     
     
208. LOTFI F, Rashidian H, Hadji M, Mohebbi E, et al
     Exposure to second-hand smoke and risk of lung cancer among Iranian population: A multicenter case-control study.
     PLoS One. 2024;19:e0306517.
     PubMed     Abstract available
     
     
     
209. HAO H, Maeda Y, Fukazawa T, Yamatsuji T, et al
     Correction: Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer.
     PLoS One. 2024;19:e0307052.
     PubMed     Abstract available
     
     
     
210. VAN DEN BOSSCHE J, De Laere M, Deschepper K, Germonpre P, et al
     Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
     PLoS One. 2024;19:e0307204.
     PubMed     Abstract available
     
     
     
211. ARMIJO N, Salas C, Espinoza N, Espinoza M, et al
     Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non-small cell lung cancer in the context of the Chilean health care system.
     PLoS One. 2024;19:e0307473.
     PubMed     Abstract available
     
     
     
212. CHEN XP, He SX, Chen MY, Chen FB, et al
     Meta-analysis of the accuracy for RASSF1A methylation in bronchial aspirates for the diagnosis of lung cancer.
     PLoS One. 2024;19:e0299447.
     PubMed     Abstract available
     
     
     
213. SIL BK, Jamiruddin MR, Paul PK, Aekwattanaphol N, et al
     Ascorbic acid as serine protease inhibitor in lung cancer cell line and human serum albumin.
     PLoS One. 2024;19:e0303706.
     PubMed     Abstract available
     
     
     
214. LIANG Y, Maeda O, Kondo C, Nishida K, et al
     Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma.
     PLoS One. 2024;19:e0307580.
     PubMed     Abstract available
     
     
     
215. MATSUMOTO H, Fukushima T, Kobayashi N, Higashino Y, et al
     High red blood cell distribution width attenuates the effectiveness of Immune checkpoint inhibitor therapy: An exploratory study using a clinical data warehouse.
     PLoS One. 2024;19:e0299760.
     PubMed     Abstract available
     
     
     
216. HUMMELINK K, van der Noort V, Muller M, Schouten RD, et al
     Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer.
     PLoS One. 2024;19:e0293707.
     PubMed     Abstract available
     
     
     
217. KOUHMAREH K, Martin E, Finlay D, Bhadada A, et al
     Capture of circulating metastatic cancer cell clusters from lung cancer patients can reveal unique genomic profiles and potential anti-metastatic molecular targets: A proof-of-concept study.
     PLoS One. 2024;19:e0306450.
     PubMed     Abstract available
     
     
     
218. SCHOUTEN RD, Schouten I, Schuurbiers MMF, van der Noort V, et al
     Optimising primary molecular profiling in non-small cell lung cancer.
     PLoS One. 2024;19:e0290939.
     PubMed     Abstract available
     
     
     
219. KISS N, Ugalde A, Prado CM, Denehy L, et al
     Living with low muscle mass and its impact throughout curative treatment for lung cancer: A qualitative study.
     PLoS One. 2024;19:e0304003.
     PubMed     Abstract available
     
     
     
220. PETERS HA, Weiss D, Boschheidgen M, Mamlins E, et al
     Prognostic potential of integrated morphologic and metabolic parameters of pre-therapeutic [18F]FDG-PET/CT regarding progression-free survival (PFS) and overall survival (OS) in NSCLC-patients.
     PLoS One. 2024;19:e0307998.
     PubMed     Abstract available
     
     
     
221. SAJJADI SF, Salehi N, Sadeghi M
     Comprehensive integrated single-cell RNA sequencing analysis of brain metastasis and glioma microenvironment: Contrasting heterogeneity landscapes.
     PLoS One. 2024;19:e0306220.
     PubMed     Abstract available
     
     
     
222. ITO M, Koido S, Iwamoto T, Morimoto S, et al
     Enhancing the immunogenicity of Wilms tumor 1 epitope in mesothelioma cells with immunoproteasome inhibitors.
     PLoS One. 2024;19:e0308330.
     PubMed     Abstract available
     
     
     
223. SARAJI A, Wulf K, Stegmann-Frehse J, Kang D, et al
     Comprehensive transcriptomic analysis of prostate cancer lung metastases.
     PLoS One. 2024;19:e0306525.
     PubMed     Abstract available
     
     
     
224. ANANDAKRISHNAN R, Shahidi R, Dai A, Antony V, et al
     An approach for developing a blood-based screening panel for lung cancer based on clonal hematopoietic mutations.
     PLoS One. 2024;19:e0307232.
     PubMed     Abstract available
     
     
     
225. MA Y, Li Z, Li D, Zheng B, et al
     G0 arrest gene patterns to predict the prognosis and drug sensitivity of patients with lung adenocarcinoma.
     PLoS One. 2024;19:e0309076.
     PubMed     Abstract available
     
     
     
226. KILDAHL-ANDERSEN A, Hofstad EF, Solberg OV, Sorger H, et al
     Navigated ultrasound bronchoscopy with integrated positron emission tomography-A human feasibility study.
     PLoS One. 2024;19:e0305785.
     PubMed     Abstract available
     
     
     
227. YU SC, Huang JY, Cheng YF, Cheng CY, et al
     Prognostic factors in clinical stage IIIA small cell lung cancer: An analysis of a population-based cancer registry in Taiwan.
     PLoS One. 2024;19:e0297399.
     PubMed     Abstract available
     
     
     
228. LAI GS, Chen CS, Cheng JC, Li JR, et al
     Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients.
     PLoS One. 2024;19:e0309941.
     PubMed     Abstract available
     
     
     
229. LIN L, Deng L, Bao Y
     Identifying crucial lncRNAs and mRNAs in hypoxia-induced A549 lung cancer cells and investigating their underlying mechanisms via high-throughput sequencing.
     PLoS One. 2024;19:e0307954.
     PubMed     Abstract available
     
     
     
230. 
     Correction: The efficacy of machine learning models in lung cancer risk prediction with explainability.
     PLoS One. 2024;19:e0310604.
     PubMed     Abstract available
     
     
     
231. PIRES DC, Arueira Chaves L, Dantas Cardoso CH, Faria LV, et al
     Effects of low dose computed tomography (LDCT) on lung cancer screening on incidence and mortality in regions with high tuberculosis prevalence: A systematic review.
     PLoS One. 2024;19:e0308106.
     PubMed     Abstract available
     
     
     
232. WU X, Li W, Chen Y
     Differences in the risk association of TERT-CLPTM1L rs4975616 (A>G) with lung cancer between Caucasian and Asian populations: A meta-analysis.
     PLoS One. 2024;19:e0309747.
     PubMed     Abstract available
     
     
     
233. FANIZZI A, Fadda F, Maddalo M, Saponaro S, et al
     Developing an ensemble machine learning study: Insights from a multi-center proof-of-concept study.
     PLoS One. 2024;19:e0303217.
     PubMed     Abstract available
     
     
     
234. GEUBBELMANS M, Claes J, Nijsten K, Gervois P, et al
     Optimization of whole slide imaging scan settings for computer vision using human lung cancer tissue.
     PLoS One. 2024;19:e0309740.
     PubMed     Abstract available
     
     
     
235. KIM T, Choe J, Shin SH, Jeong BH, et al
     Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib.
     PLoS One. 2024;19:e0310079.
     PubMed     Abstract available
     
     
     
236. JAIN R, Singh P, Abdelkader M, Boulila W, et al
     Efficient lung cancer detection using computational intelligence and ensemble learning.
     PLoS One. 2024;19:e0310882.
     PubMed     Abstract available
     
     
     
237. DJERIDI Z, Ghouar A, Boulares H, Bouye M, et al
     Applications of the prediction of satisfaction design for monitoring single-arm phase II trials.
     PLoS One. 2024;19:e0305814.
     PubMed     Abstract available
     
     
     
238. HUANG H, Li L, Tong L, Luo H, et al
     Perioperative PD-1/PD-L1 inhibitors for resectable non-small cell lung cancer: A meta-analysis based on randomized controlled trials.
     PLoS One. 2024;19:e0310808.
     PubMed     Abstract available
     
     
     
239. XIE J, He Y, Che S, Zhao W, et al
     Differential diagnosis of benign and lung adenocarcinoma presenting as larger solid nodules and masses based on multiscale CT radiomics.
     PLoS One. 2024;19:e0309033.
     PubMed     Abstract available
     
     
     
240. NAGAMINE H, Yashiro M, Mizutani M, Sugimoto A, et al
     Insulin-like growth factor 1 receptor expression correlates with programmed death ligand 1 expression and poor survival in non-small cell lung cancer.
     PLoS One. 2024;19:e0297397.
     PubMed     Abstract available
     
     
     
241. STOVERUD KH, Bouget D, Pedersen A, Leira HO, et al
     AeroPath: An airway segmentation benchmark dataset with challenging pathology and baseline method.
     PLoS One. 2024;19:e0311416.
     PubMed     Abstract available
     
     
     
242. NDUAGUBA SO, Kelly KM
     Multilevel factors associated with delays in screening, diagnosis, and treatment for lung cancer-A mixed methods systematic review protocol.
     PLoS One. 2024;19:e0309196.
     PubMed     Abstract available
     
     
     
243. PENG J, Xu H, Liu Q
     Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis.
     PLoS One. 2024;19:e0312133.
     PubMed     Abstract available
     
     
     
244. CHEN H, Hu XB, Zhou J, He CY, et al
     Association of chronic obstructive pulmonary disease with risk of lung cancer in individuals aged 40 years and older: A cross-sectional study based on NHANES 2013-2018.
     PLoS One. 2024;19:e0311537.
     PubMed     Abstract available
     
     
     
245. GREGORY MD, Ofosu-Asante K, Lazarte JMS, Puente PE, et al
     Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis.
     PLoS One. 2024;19:e0312563.
     PubMed     Abstract available
     
     
     
246. MAHJABEEN A, Hasan MZ, Rahman MT, Islam MA, et al
     Genetic insights into the connection between pulmonary TB and non-communicable diseases: An integrated analysis of shared genes and potential treatment targets.
     PLoS One. 2024;19:e0312072.
     PubMed     Abstract available
     
     
     
247. LV Z, Liu P, Yang Y, Ji J, et al
     (-)-Epicatechin regulates endoplasmic reticulum stress and promotes ferroptosis in lung cancer cells via the PERK/eIF2alpha/ATF4 signaling pathway.
     PLoS One. 2024;19:e0313010.
     PubMed     Abstract available
     
     
     
248. SUZUKI S, Yashiro M, Izumi N, Tsukioka T, et al
     Impact of CA9 expression in the diagnosis of lymph-node metastases in non-small cell lung cancer based on [18F]FDG PET/CT.
     PLoS One. 2024;19:e0312846.
     PubMed     Abstract available
     
     
     
249. PAVEL MA, Islam R, Babor SB, Mehadi R, et al
     Non-small cell lung cancer detection through knowledge distillation approach with teaching assistant.
     PLoS One. 2024;19:e0306441.
     PubMed     Abstract available
     
     
     
250. YANG Y, Li J, Wang Y, Luo L, et al
     Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis.
     PLoS One. 2024;19:e0312605.
     PubMed     Abstract available
     
     
     
251. 
     Retraction: Differential Expression of the RANKL/RANK/OPG System Is Associated with Bone Metastasis in Human Non-Small Cell Lung Cancer.
     PLoS One. 2024;19:e0314046.
     PubMed    
     
     
     
252. LIAO Y, Zhou Y, Zhou X, Chen J, et al
     Gastroesophageal reflux disease and risk of incident lung cancer: A large prospective cohort study in UK Biobank.
     PLoS One. 2024;19:e0311758.
     PubMed     Abstract available
     
     
     
253. CAI S, Yang W, Luo H, Li Z, et al
     Clinical features and prognostic factors of IV combined small cell lung cancer: A propensity score matching analysis.
     PLoS One. 2024;19:e0313221.
     PubMed     Abstract available
     
     
     
254. SLOMKA J, Berthou H, Mansuet-Lupo A, Blons H, et al
     Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.
     PLoS One. 2024;19:e0307161.
     PubMed     Abstract available
     
     
     
255. DONG Y, Li S, Che G
     Is it safe and feasible to use multi-lateral-pores drainage strategy after video-assisted thoracoscopic surgery?
     PLoS One. 2024;19:e0313176.
     PubMed     Abstract available
     
     
     
256. BONERT M, Schittenhelm J, Begum H, Lu JQ, et al
     Neuroanatomical location of lung cancer brain metastases in 234 patients with a focus on cancer subtyping and biomarkers.
     PLoS One. 2024;19:e0314205.
     PubMed     Abstract available
     
     
     
257. ZHANG E, Feng X, Liu F, Zhang P, et al
     Correction: Roles of PI3K/Akt and c-Jun Signaling Pathways in Human Papillomavirus Type 16 Oncoprotein-Induced HIF-1alpha, VEGF, and IL-8 Expression and In Vitro Angiogenesis in Non-Small Cell Lung Cancer Cells.
     PLoS One. 2024;19:e0314378.
     PubMed     Abstract available
     
     
     
258. YADAV DP, Sharma B, Webber JL, Mehbodniya A, et al
     EDTNet: A spatial aware attention-based transformer for the pulmonary nodule segmentation.
     PLoS One. 2024;19:e0311080.
     PubMed     Abstract available
     
     
     
259. GUIBIN D, Xiaolan S, Wei Z, Xiaoli L, et al
     Prediction of iodine-125 seed implantation efficacy in lung cancer using an enhanced CT-based nomogram model.
     PLoS One. 2024;19:e0313570.
     PubMed     Abstract available
     
     
     
260. WANG S, Yan H, Wen J, Zhou Z, et al
     Risk factors for conversion to thoracotomy in patients with lung cancer undergoing video-assisted thoracoscopic surgery: A meta-analysis.
     PLoS One. 2024;19:e0313236.
     PubMed     Abstract available
     
     
     
261. ARUNACHALAM A, Sura S, Murphy J, Conkling P, et al
     Real-world treatment patterns and outcomes among unresectable stage III non-small cell lung cancer.
     PLoS One. 2024;19:e0314156.
     PubMed     Abstract available
     
     
     
262. JIANG HN, Zeng B, Zhang Y, Daskoulidou N, et al
     Correction: Involvement of TRPC Channels in Lung Cancer Cell Differentiation and the Correlation Analysis in Human Non-Small Cell Lung Cancer.
     PLoS One. 2024;19:e0315242.
     PubMed     Abstract available
     
     
     
263. WEINSTEIN SJ, Parisi D, Mondul AM, Layne TM, et al
     Vitamin D binding protein genetic isoforms, serum vitamin D, and cancer risk in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
     PLoS One. 2024;19:e0315252.
     PubMed     Abstract available
     
     
     
264. JALILIAN H, Heydari S, Javanshir E, Jamebozorgi K, et al
     Hospitalization costs and out-of-pocket (OOP) payment in lung cancer patients in Iran: Health Sector Evolution Plan (HSEP) has reduced OOP payments and improved financial protection.
     PLoS One. 2024;19:e0297934.
     PubMed     Abstract available
     
     
     
265. CHATWICHIEN J, Semakul N, Yimklan S, Suwanwong N, et al
     Lutein derived from Xenostegia tridentata exhibits anticancer activities against A549 lung cancer cells via hyaluronidase inhibition.
     PLoS One. 2024;19:e0315570.
     PubMed     Abstract available
     
     
     
266. YUAN S, Ou W, Mi X, Hou J, et al
     Enhancing lobaplatin sensitivity in lung adenocarcinoma through inhibiting LDHA-targeted metabolic pathways.
     PLoS One. 2024;19:e0310825.
     PubMed     Abstract available
     
     
     
267. KLIMONTOVA M, Zhang H, Campos-Laborie F, Webster N, et al
     THUMPD3 regulates alternative splicing of ECM transcripts in human lung cancer cells and promotes proliferation and migration.
     PLoS One. 2024;19:e0314655.
     PubMed     Abstract available
     
     
     
268. HANAOKA S, Nomura Y, Hayashi N, Sato I, et al
     Deep generative abnormal lesion emphasization validated by nine radiologists and 1000 chest X-rays with lung nodules.
     PLoS One. 2024;19:e0315646.
     PubMed     Abstract available
     
     
     
269. ZHANG H, Liu S, Zhang J, Wang Y, et al
     CD47 expression in non-small cell lung cancer and its relationship with tumor-associated macrophage infiltration.
     PLoS One. 2024;19:e0314228.
     PubMed     Abstract available
     
     
     
270. ROMASZKO-WOJTOWICZ A, Doboszynska A, Piechnik A, Kuziemski K, et al
     Impact of the COVID-19 pandemic on lung cancer diagnosis in northern Poland-addressing the COVID-19 debt.
     PLoS One. 2024;19:e0316261.
     PubMed     Abstract available
     
     
     
271. SAIT ARW, AlBalawi E, Nagaraj R
     Ensemble learning driven Kolmogorov-Arnold Networks-based Lung Cancer classification.
     PLoS One. 2024;19:e0313386.
     PubMed     Abstract available
     
     
     
272. SALAZAR P, Cheung P, Ganeshan B, Oikonomou A, et al
     Predefined and data-driven CT radiomics predict recurrence-free and overall survival in patients with pulmonary metastases treated with stereotactic body radiotherapy.
     PLoS One. 2024;19:e0311910.
     PubMed     Abstract available
     
     
     
273. SAETANG M, Kunapaisal T, Wasinwong W, Boonthum P, et al
     Predictors associated with Clavien-Dindo complications in lung cancer surgery: A retrospective cohort study.
     PLoS One. 2024;19:e0316214.
     PubMed     Abstract available
     
     
     
274. DU L, Ren W, Liu L, Zhu H, et al
     SH2D5 promotes lung adenocarcinoma cell metastasis and triggers EMT via activating AKT signaling pathway.
     PLoS One. 2024;19:e0316432.
     PubMed     Abstract available
     
     
     January 2023
275. LIU Y
     Identification and comprehensive analysis of super-enhancer related genes involved in epithelial-to-mesenchymal transition in lung adenocarcinoma.
     PLoS One. 2023;18:e0291088.
     PubMed     Abstract available
     
     
     
276. ZHOU D, Zhai X, Zhang R
     Ribonucleotide reductase regulatory subunit M2 (RRM2) as a potential sero-diagnostic biomarker in non-small cell lung cancer.
     PLoS One. 2023;18:e0291461.
     PubMed     Abstract available
     
     
     
277. DAEI SORKHABI A, Fazlollahi A, Sarkesh A, Aletaha R, et al
     Efficacy and safety of veliparib plus chemotherapy for the treatment of lung cancer: A systematic review of clinical trials.
     PLoS One. 2023;18:e0291044.
     PubMed     Abstract available
     
     
     
278. WU M, Liu S, Wang C, Wu Y, et al
     Risk factors for mortality among lung cancer patients with covid-19 infection: A systematic review and meta-analysis.
     PLoS One. 2023;18:e0291178.
     PubMed     Abstract available
     
     
     
279. LIU Y, Yan M
     Trends in all causes and cause specific mortality attributable to ambient particulate matter pollution in China from 1990 to 2019: A secondary data analysis study.
     PLoS One. 2023;18:e0291262.
     PubMed     Abstract available
     
     
     
280. 
     Retraction: Frondoside A Suppressive Effects on Lung Cancer Survival, Tumor Growth, Angiogenesis, Invasion, and Metastasis.
     PLoS One. 2023;18:e0291478.
     PubMed    
     
     
     
281. FUJIKAWA K, Saito T, Kurose K, Kojima T, et al
     Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors.
     PLoS One. 2023;18:e0291772.
     PubMed     Abstract available
     
     
     
282. LEROY K, Audigier Valette C, Alexandre J, Boussemart L, et al
     Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study).
     PLoS One. 2023;18:e0291495.
     PubMed     Abstract available
     
     
     
283. BINGHAM SL, Small S, Semple CJ
     A qualitative evaluation of a multi-modal cancer prehabilitation programme for colorectal, head and neck and lung cancers patients.
     PLoS One. 2023;18:e0277589.
     PubMed     Abstract available
     
     
     
284. IKEMOTO S, Sakurai F, Tokuoka S, Yamashita T, et al
     Novel conditionally replicating adenovirus-mediated efficient detection of circulating tumor cells in lung cancer patients.
     PLoS One. 2023;18:e0286323.
     PubMed     Abstract available
     
     
     
285. WESTEEL V, Schuette W, Urban T, Radonjic D, et al
     Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.
     PLoS One. 2023;18:e0292307.
     PubMed     Abstract available
     
     
     
286. ROUNIS K, Makrakis D, Papadaki C, Monastirioti A, et al
     Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
     PLoS One. 2023;18:e0294382.
     PubMed     Abstract available
     
     
     
287. MAKRAKIS D, Rounis K, Tsigkas AP, Georgiou A, et al
     Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
     PLoS One. 2023;18:e0294384.
     PubMed     Abstract available
     
     
     
288. PENG B, Ling X, Huang T, Wan J, et al
     HSP70 via HIF-1 alpha SUMOylation inhibits ferroptosis inducing lung cancer recurrence after insufficient radiofrequency ablation.
     PLoS One. 2023;18:e0294263.
     PubMed     Abstract available
     
     
     
289. LIMBU S, McCloskey KE
     Stemness genes and miR-1247-3p expression associate with clinicopathological parameters and prognosis in lung adenocarcinoma.
     PLoS One. 2023;18:e0294171.
     PubMed     Abstract available
     
     
     
290. AIN NAZIR NU, Shaukat MH, Luo R, Abbas SR, et al
     Novel breath biomarkers identification for early detection of hepatocellular carcinoma and cirrhosis using ML tools and GCMS.
     PLoS One. 2023;18:e0287465.
     PubMed     Abstract available
     
     
     
291. NIBID L, Greco C, Cordelli E, Sabarese G, et al
     Deep pathomics: A new image-based tool for predicting response to treatment in stage III non-small cell lung cancer.
     PLoS One. 2023;18:e0294259.
     PubMed     Abstract available
     
     
     
292. ARBEE-KALIDAS N, Moutlana HJ, Moodley Y, Kebalepile MM, et al
     The association between cardiopulmonary exercise testing and postoperative outcomes in patients with lung cancer undergoing lung resection surgery: A systematic review and meta-analysis.
     PLoS One. 2023;18:e0295430.
     PubMed     Abstract available
     
     
     
293. NEMLANDER E, Rosenblad A, Abedi E, Ekman S, et al
     Correction: Lung cancer prediction using machine learning on data from a symptom e-questionnaire for never smokers, formers smokers and current smokers.
     PLoS One. 2023;18:e0295780.
     PubMed     Abstract available
     
     
     
294. WANG J, Wang H, Xu J, Song Q, et al
     Identification of protein signatures for lung cancer subtypes based on BPSO method.
     PLoS One. 2023;18:e0294243.
     PubMed     Abstract available
     
     
     
295. WU YY, Shen WB, Li JW, Liu MY, et al
     Targeted metabolomics reveals the association between central carbon metabolism and pulmonary nodules.
     PLoS One. 2023;18:e0295276.
     PubMed     Abstract available
     
     
     
296. 
     Retraction: Restoration of Mal overcomes the defects of apoptosis in lung cancer cells.
     PLoS One. 2023;18:e0296552.
     PubMed    
     
     
     
297. 
     Correction: Nicotine Promotes Tumor Growth and Metastasis in Mouse Models of Lung Cancer.
     PLoS One. 2023;18:e0296477.
     PubMed     Abstract available
     
     
     
298. TIAN W, Guo Q, Fu D, Ma X, et al
     Efficacy and safety profile of combining antiangiogenic agents with chemotherapy in patients with advanced malignant pleural mesothelioma: A systematic review and meta-analysis of randomized controlled trials.
     PLoS One. 2023;18:e0295745.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum